Why faster trials make participant understanding more important than ever
July 15, 2026 | Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
“I was confused, didn’t understand half of what he was saying.” The clinician’s reply? “You’ll only retain 2% of what’s discussed.” Then they carried on. They didn’t go back.*
That isn’t how anyone should describe the conversation that determines whether they join a clinical trial. Regulatory reforms are removing unnecessary delays from study approval and start-up, but there’s one part of the process that can’t be compressed: ensuring people genuinely understand what they’re agreeing to.
Longer forms, same confusion
When consent comes up, the instinct is to add more: more detail, more pages, more risks spelled out. The result is documents that are comprehensive, yet largely unread.
One participant, three infusions into a cancer trial, put it plainly: “The list of potential side effects goes on for many pages. Before I could give informed consent, the risks were laid out in exacting detail. It’s hard to stay alert.”*
Patients who go looking for answers often come away with more questions. “I spent a night searching the internet and found nothing useful,” one wrote, “just terrifying statistics and medical jargon written for doctors.”*
These people weren’t asking for less information – they were asking for information they could actually understand. Because disclosure alone isn’t the same as understanding.
Consent is a conversation, not a signature
The problem isn’t always the consent form itself. Sometimes it’s what happens around it. A research coordinator, describing their own site, said the doctor “always pushes for them to sign the consent form without fully understanding the trial,” on the logic that “they’ll learn more as time goes on.” And if a participant asks to take the form home to read, or talk it over with their GP? That’s “looked at as a bad thing, since we might lose the patient.”*
That’s understandable when recruitment timelines are under pressure. But it’s also where informed consent can quietly become a process of collecting signatures rather than building understanding.
People need time to reflect, ask questions, involve family members or speak to healthcare professionals they trust. A signature doesn’t demonstrate understanding. A conversation does.
Clearer isn’t simpler
The goal of informed consent isn’t simply to disclose every possible piece of information. It’s to present information in a way people can understand, use, and act on – using plain language, structuring information logically, introducing visuals where they genuinely aid understanding, and layering information so participants can explore topics in more depth at their own pace.
And it has to work for everyone a trial hopes to reach: older participants, people with lower health literacy, caregivers deciding alongside a patient, and anyone moving between an app and a face-to-face conversation. None of that is a special accommodation. It’s just consent that works.
Why this matters more as trials speed up
Regulatory reforms such as Operation TrialBlazer, the EU Clinical Trials Regulation and the MHRA’s changes around proportionate, risk-based review are all designed to make clinical research more efficient, with faster timelines. That’s good news for patients waiting for new treatments.
Speed may shorten timelines, but it can’t shorten the responsibility to ensure genuine understanding. When people don’t fully understand what they’re joining, uncertainty doesn’t disappear after enrolment. It can resurface later as hesitation, withdrawal, missed assessments or poorer engagement throughout the study. Those challenges affect participant experience, recruitment, retention and ultimately the quality of the data a trial generates.
As trials become faster, understanding – not disclosure – becomes the measure of good consent.
Let’s talk
Clearer consent. Information people can actually use. Materials built for the full range of participants. If your study is picking up pace and you want the people in it to understand what they’re joining – and stay – let’s talk.
*We searched our index of patient and participant discussion for where people describe consenting to, or trying to understand, a clinical trial. The quotes are real, lightly edited for length, with identifying details removed. It’s a self-selected, anonymous source – illustrative, not statistically representative – but it shows, in patients’ own words, where consent is and isn’t working.
References
- US Department of Health and Human Services. Press release. Available here (accessed July 2026).
- Regulation (EU) No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use (Clinical Trials Regulation).
- Health Research Authority. Clinical trials regulation reform. Available here (accessed July 2026).
- Health Research Authority. Informing participants and seeking consent. Available here (accessed July 2026).
- NHS England. Inclusive digital healthcare: a framework for NHS action on digital inclusion. Available here (accessed July 2026).
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.